<DOC>
	<DOCNO>NCT02548962</DOCNO>
	<brief_summary>Phase 1 open-label , dose finding , multicenter study ibrutinib combination pomalidomide dexamethasone subject relapsed/refractory multiple myeloma . Phase 2b conducted randomize , double-blind , multicenter study ibrutinib placebo , combination pomalidomide dexamethasone subject relapsed/refractory multiple myeloma .</brief_summary>
	<brief_title>Study Ibrutinib Combination With Pomalidomide Dexamethasone Subjects With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>Bruton 's tyrosine kinase ( Btk ) enzyme present hematopoietic cell T cell necessary downstream signal transduction various hematopoietic receptor include B cell receptor well Fc , chemokine , adhesion receptor , crucial B cell development osteoclastogenesis . Although down-regulated normal plasma cell , Btk highly express malignant cell many myeloma patient cell line . Ibrutinib potent specific inhibitor Btk currently Phase 2 3 clinical trial . The current study design intend determine safety efficacy ibrutinib combination pomalidomide dexamethasone subject relapsed/refractory multiple myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subjects relapsed/refractory MM receive least two prior line therapy include lenalidomide either bortezomib carfilzomib demonstrate disease progression within 60 day completion recent treatment regimen . Measurable disease define least ONE following : 1 . Serum monoclonal protein ( SPEP ) ≥1 g/dL . 2 . Urine monoclonal protein ( UPEP ) ≥200 mg 24 hour urine . Adequate hematologic , hepatic , renal function ECOG performance status ≤ 2 Subject must primary refractory disease Plasma cell leukemia , primary amyloidosis POEMS syndrome Unable swallow capsule disease significantly affect gastrointestinal function Requires treatment strong CYP3A inhibitor Women pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Bruton 's Tyrosine Kinase</keyword>
	<keyword>PCI-32765</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Relapsed Refractory Multiple Myeloma</keyword>
	<keyword>Ibrutinib</keyword>
</DOC>